Panion & Bf Biotech Bilan de santé

Santé financière contrôle des critères 5/6

Panion & Bf Biotech possède un total de capitaux propres de NT$1.9B et une dette totale de NT$637.7M, ce qui porte son ratio d'endettement à 33.9%. Son actif total et son passif total sont NT$3.1B et de NT$1.3B. L'EBIT de Panion & Bf Biotech est NT$208.7M ce qui fait que son ratio de couverture des intérêts 77.4. Elle dispose de liquidités et de placements à court terme de NT$442.7M.

Informations clés

33.9%

Ratio d'endettement

NT$637.65m

Dette

Ratio de couverture des intérêts	77.4x
Argent liquide	NT$442.70m
Fonds propres	NT$1.88b
Total du passif	NT$1.26b
Total des actifs	NT$3.14b

Mises à jour récentes de la santé financière

Recent updates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Aug 13

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Apr 07

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Mar 03

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

Feb 04

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

Jan 09

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Dec 14

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 1760 ( NT$1.4B ) dépassent ses passifs à court terme ( NT$1.0B ).

Passif à long terme: Les actifs à court terme de 1760 ( NT$1.4B ) dépassent ses passifs à long terme ( NT$259.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 1760 ( 10.4% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 1760 est passé de 0% à 33.9% au cours des 5 dernières années.

Couverture de la dette: La dette de 1760 est bien couverte par le flux de trésorerie opérationnel ( 59.6% ).

Couverture des intérêts: Les paiements d'intérêts de 1760 sur sa dette sont bien couverts par l'EBIT ( 77.4 x couverture).

Panion & Bf Biotech Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Panion & Bf Biotech Inc. to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings released: EPS: NT$0.23 (vs NT$0.20 in 2Q 2023)

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Panion & Bf Biotech Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$1.50 per share

Panion & Bf Biotech Inc. Announces the Cash Dividend, Payable on July 10, 2024

Panion & Bf Biotech Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$0.90 (vs NT$2.13 in FY 2022)

Panion & Bf Biotech Inc., Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Panion and BF Biotech Inc. Obtains Nephoxil NDA Approval

Panion & Bf Biotech Inc. Announces Nephoxil Receives NMPA Acceptance for NDA Application Submission

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$1.88 in 2Q 2022)

Upcoming dividend of NT$2.00 per share at 1.5% yield

Panion & Bf Biotech Inc. Announces the Cash Dividend, payable on August 11, 2023

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: NT$2.13 (vs NT$1.32 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.91 (vs NT$0.77 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.88 (vs NT$0.97 in 2Q 2021)

Upcoming dividend of NT$1.50 per share

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: NT$0.46 (vs NT$0.32 loss in 1Q 2021)

Price target increased to NT$106

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$0.77 (vs NT$0.038 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.97 (vs NT$0.099 loss in 2Q 2020)

Upcoming dividend of NT$0.70 per share

Price target increased to NT$108

First quarter 2021 earnings released: NT$0.32 loss per share (vs NT$0.009 profit in 1Q 2020)

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Full year 2020 earnings released: EPS NT$0.36 (vs NT$2.10 in FY 2019)

Panion & Bf Biotech Inc., Annual General Meeting, Jun 04, 2021

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

New 90-day low: NT$74.10

Price target lowered to NT$97.00

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

New 90-day low: NT$80.60

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

New 90-day low: NT$91.10

Third quarter 2020 earnings released: NT$0.04 loss per share

Revenue misses expectations

New 90-day low: NT$104

New 90-day low: NT$112

Price target raised to NT$141

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines